Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melasyl Serum vs Hydroquinone Post-Laser for Melasma and Post-Acne Hyperpigmentation
NCT07121439Not yet recruiting
- Start
- Sep 2025
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of thiopyridinone in melasma and Post-inflammatory hyperpigmentation (PIH) (2 arms). Primary endpoints: Change of Subjective Pain Evaluation at 4 weeks, Change of Erythema Score at 4 weeks and 6 more. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
thiopyridinone
03
Conditions
melasmaPost-inflammatory hyperpigmentation (PIH)
Beyond the preview
Go deeper on NCT07121439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07121439.